Cohen & Steers Reports Mixed Q4 2025 Results with GAAP EPS Decline Due to One-Time Costs
CNS sits 18% above its 52-week low of $58.39.
Summary
Cohen & Steers reported Q4 2025 results with GAAP diluted EPS of $0.68, a decrease from prior periods, largely due to $10.8 million in non-recurring expenses. However, adjusted diluted EPS remained stable at $0.81, alongside positive net inflows and revenue growth.
Key Events · Earnings and Guidance · CNS
-
Q4 2025 GAAP EPS Decline
Diluted EPS for the fourth quarter of 2025 was $0.68, a decrease from $0.81 in Q3 2025 and $0.89 in Q4 2024.
-
Impact of Non-Recurring Expenses
GAAP results were significantly impacted by $10.8 million in non-recurring expenses related to a closed-end fund rights offering, which also reduced the operating margin to 28.0%.
-
Stable Adjusted EPS
Adjusted diluted EPS remained stable at $0.81 for Q4 2025, matching Q3 2025 and increasing from $0.78 in Q4 2024.
-
Positive Net Inflows
The company reported $1.2 billion in net inflows for the fourth quarter, contributing to an ending AUM of $90.5 billion.
Analysis · CNS · Finance
Cohen & Steers reported a notable decline in GAAP diluted EPS for Q4 2025, primarily driven by $10.8 million in non-recurring expenses related to a closed-end fund rights offering. While the GAAP figures show a significant year-over-year and sequential decrease, the adjusted diluted EPS remained stable, and the company achieved positive net inflows and revenue growth. Investors should analyze the adjusted metrics and the one-time nature of the expenses to assess the underlying operational health, as these factors mitigate the headline GAAP miss.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNS was trading at $68.78 on NYSE in the Finance sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $58.39 to $91.07. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.